GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182057 | Esophagus | HGIN | peptidyl-lysine modification | 88/2587 | 376/18723 | 2.99e-07 | 1.39e-05 | 88 |
GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
GO:00064735 | Esophagus | HGIN | protein acetylation | 45/2587 | 201/18723 | 6.17e-04 | 8.58e-03 | 45 |
GO:00310568 | Esophagus | HGIN | regulation of histone modification | 36/2587 | 152/18723 | 7.06e-04 | 9.52e-03 | 36 |
GO:00183945 | Esophagus | HGIN | peptidyl-lysine acetylation | 39/2587 | 169/18723 | 7.46e-04 | 9.90e-03 | 39 |
GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
GO:00064755 | Esophagus | HGIN | internal protein amino acid acetylation | 36/2587 | 160/18723 | 1.87e-03 | 2.01e-02 | 36 |
GO:00310574 | Esophagus | HGIN | negative regulation of histone modification | 14/2587 | 46/18723 | 2.80e-03 | 2.74e-02 | 14 |
GO:00183935 | Esophagus | HGIN | internal peptidyl-lysine acetylation | 35/2587 | 158/18723 | 2.82e-03 | 2.75e-02 | 35 |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
GO:20007564 | Esophagus | ESCC | regulation of peptidyl-lysine acetylation | 43/8552 | 63/18723 | 2.43e-04 | 1.50e-03 | 43 |
GO:19019835 | Esophagus | ESCC | regulation of protein acetylation | 49/8552 | 77/18723 | 1.12e-03 | 5.60e-03 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THAP7 | SNV | Missense_Mutation | rs755408769 | c.392N>A | p.Arg131Gln | p.R131Q | Q9BT49 | protein_coding | tolerated(0.69) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
THAP7 | SNV | Missense_Mutation | rs754815287 | c.667G>A | p.Gly223Arg | p.G223R | Q9BT49 | protein_coding | tolerated(0.08) | probably_damaging(0.998) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
THAP7 | SNV | Missense_Mutation | | c.832G>C | p.Glu278Gln | p.E278Q | Q9BT49 | protein_coding | tolerated(0.07) | probably_damaging(0.932) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
THAP7 | SNV | Missense_Mutation | novel | c.386N>G | p.Glu129Gly | p.E129G | Q9BT49 | protein_coding | tolerated(0.1) | benign(0) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
THAP7 | SNV | Missense_Mutation | rs755408769 | c.392G>C | p.Arg131Pro | p.R131P | Q9BT49 | protein_coding | tolerated(0.29) | benign(0) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
THAP7 | SNV | Missense_Mutation | | c.572N>A | p.Cys191Tyr | p.C191Y | Q9BT49 | protein_coding | tolerated(0.27) | benign(0) | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
THAP7 | SNV | Missense_Mutation | rs755408769 | c.392N>A | p.Arg131Gln | p.R131Q | Q9BT49 | protein_coding | tolerated(0.69) | benign(0) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
THAP7 | SNV | Missense_Mutation | novel | c.161G>T | p.Trp54Leu | p.W54L | Q9BT49 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
THAP7 | SNV | Missense_Mutation | rs755408769 | c.392N>A | p.Arg131Gln | p.R131Q | Q9BT49 | protein_coding | tolerated(0.69) | benign(0) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
THAP7 | deletion | Frame_Shift_Del | | c.343delN | p.Ala115LeufsTer156 | p.A115Lfs*156 | Q9BT49 | protein_coding | | | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |